| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLEK |
| Uniprot No | P08567 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350 aa |
| 活性数据 | MEPKRIREGY LVKKGSVFNT WKPMWVVLLE DGIEFYKKKS DNSPKGMIPL KGSTLTSPCQ DFGKRMFVFK ITTTKQQDHF FQAAFLEERD AWVRDIKKAI KCIEGGQKFA RKSTRRSIRL PETIDLGALY LSMKDTEKGI KELNLEKDKK IFNHCFTGNC VIDWLVSNQS VRNRQEGLMI ASSLLNEGYL QPAGDMSKSA VDGTAENPFL DNPDAFYYFP DSGFFCEENS SDDDVILKEE FRGVIIKQGC LLKQGHRRKN WKVRKFILRE DPAYLHYYDP AGAEDPLGAI HLRGCVVTSV ESNSNGRKSE EENLFEIITA DEVHYFLQAA TPKERTEWIR AIQMASRTGK |
| 分子量 | 40.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PLEK蛋白的参考文献示例(注：以下内容为模拟示例，仅供格式参考，非真实文献)：
---
1. **文献名称**： *Structural and functional analysis of recombinant human PLEKHA5 in epithelial cell adhesion*
**作者**： Zhang, L., et al.
**摘要**： 本研究成功表达并纯化了重组人PLEKHA5蛋白，通过X射线晶体学解析其PH结构域的三维结构。功能实验表明，PLEKHA5通过调控细胞骨架重塑参与上皮细胞的黏附和迁移，为癌症转移机制提供新见解。
2. **文献名称**： *Recombinant PLEKHG2 activates NF-κB signaling in macrophages*
**作者**： Tanaka, K., et al.
**摘要**： 文章报道了重组PLEKHG2蛋白的异源表达及功能验证，发现其作为RhoGEF通过激活NF-κB通路促进巨噬细胞炎症反应，提示其在自身免疫疾病中的潜在作用。
3. **文献名称**： *High-yield purification of recombinant human PLEKHF2 and its role in apoptosis regulation*
**作者**： Patel, R., & Wong, H.
**摘要**： 开发了一种高效重组PLEKHF2蛋白的纯化工艺，并证明其通过与Bcl-2家族蛋白互作调控线粒体依赖性凋亡，为相关治疗策略提供实验基础。
4. **文献名称**： *Recombinant PLEK protein as a therapeutic target for metabolic syndrome*
**作者**： Guo, Y., et al.
**摘要**： 探索重组PLEK蛋白在胰岛素信号通路中的作用，动物模型显示其抑制剂可改善胰岛素抵抗，提示PLEK作为代谢综合征治疗靶点的潜力。
---
**注意事项**：
- 上述文献为虚构示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索最新成果，使用关键词“recombinant human PLEK protein”或结合具体家族成员(如PLEKHA、PLEKHG等)进行精确查询。
- 若需真实文献，建议提供更具体的PLEK亚型或研究背景，以便进一步协助检索。
Recombinant human PLEK protein, primarily associated with the pleckstrin homology (PH) domain-containing protein family, plays critical roles in cellular signaling and immune regulation. Initially identified for its involvement in leukocyte function, PLEK (particularly PLEK1 or pleckstrin) is highly expressed in platelets and immune cells, where it modulates membrane-cytoskeleton interactions, vesicle trafficking, and inflammatory responses. Structurally, PLEK proteins feature characteristic PH domains that facilitate lipid binding and subcellular localization, enabling participation in phosphoinositide-mediated signaling pathways. Recombinant forms are engineered via expression systems like *E. coli* or mammalian cells, often tagged for purification, to study their biochemical properties or therapeutic potential. Research highlights PLEK's dual roles: as a regulator of cytoskeletal dynamics during phagocytosis and cell migration, and as a mediator of immune disorders, cancer progression, and thrombotic diseases. Dysregulation of PLEK has been linked to chronic inflammation, autoimmune conditions, and metastasis, making it a target for drug discovery. Its recombinant version serves as a vital tool for elucidating molecular mechanisms in immune signaling and evaluating inhibitors in preclinical models. Ongoing studies focus on its interplay with kinases, GTPases, and membrane phospholipids to uncover novel therapeutic strategies for inflammation-related pathologies.
×
